Nonfounder total target cash compensation increased by 4.2% at private life-science companies in 2014.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Rychlik, B. Nat. Biotechnol. 32, 393–395 (2014).
Rychlik, B. Nat. Biotechnol. 31, 259–261 (2013).
Wasserman, N. The Founder's Dilemmas: Anticipating and Avoiding the Pitfalls That Can Sink a Startup (Princeton University Press, 2012).
Wasserman, N. How an entrepreneur's passion can destroy a startup. The Wall Street Journal (25 August 2014).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Rychlik, B. Total target cash compensation shows a healthy increase at private life-science companies. Nat Biotechnol 33, 313–316 (2015). https://doi.org/10.1038/nbt.3166
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.3166
This article is cited by
-
Continuous positive compensation trends indicate a healthy private life sciences sector
Nature Biotechnology (2017)
-
Compensation inflation remains consistent at private life science companies
Nature Biotechnology (2016)